# Duchenne muscular dystrophy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/duchenne-muscular-dystrophy

> 12 upcoming FDA catalysts in Duchenne muscular dystrophy: sevasemten (EWTX) on January 2027 (primary completion); sevasemten (EWTX) on Jan to Apr 2027 (topline data readout); sevasemten (EWTX) on March 2027 (primary completion); sevasemten (EWTX) on Mar to Jun 2027 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2025 | [Vasculan® (ifetroban) topline data readout](https://sec-api.dev/pdufa/ifetroban) | CPIX | Duchenne muscular dystrophy | completed, positive | "In February 2025, Cumberland announced positive top-line results from the Phase II study evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (DMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm)) |
| February 18, 2025 | [SGT-003 interim data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne muscular dystrophy | completed, positive | "On February 18, 2025, Solid Biosciences Inc. (the "Company") announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy ("Duchenne")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312525028123/d913726d8k.htm)) |
| March 19, 2025 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed | "Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm)) |
| Jul 2025 | [INS1201 trial start](https://sec-api.dev/pdufa/ins1201) | INSM | Duchenne muscular dystrophy | completed | "Insmed dosed the first patient in the Phase 1 ASCEND clinical study of INS1201, an intrathecally-delivered gene therapy for patients with Duchenne muscular dystrophy (DMD), in July 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 28, 2025 | [Pgn-edo51 primary completion](https://sec-api.dev/pdufa/pgn-edo51) | PEPG | Duchenne Muscular Dystrophy | withdrawn | "NCT06079736 (A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor PepGen Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079736)) |
| August 31, 2025 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |
| September 24, 2025 | [Fordadistrogene movaparvovec primary completion](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) | PFE | Duchenne Muscular Dystrophy | withdrawn | "NCT05689164 (A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05689164)) |
| November 3, 2025 | [SGT-003 interim data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne muscular dystrophy | completed, positive | "On November 3, 2025, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy at a dose level of 1E14vg/kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050d8k.htm)) |
| December 3, 2025 | [Deramiocel topline data readout](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, positive | "SAN DIEGO, Dec. 3, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203xex99d1.htm)) |
| December 8, 2025 | [Rostudirsen topline data readout](https://sec-api.dev/pdufa/rostudirsen) | DYN | Duchenne muscular dystrophy | completed, positive | "WALTHAM, Mass., December 8, 2025 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced positive topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518dex991.htm)) |
| Q1 2026 | [Rinvatercept trial start](https://sec-api.dev/pdufa/rinvatercept) | KROS | Duchenne muscular dystrophy | scheduled | "Corresponding decreases in fat mass, both whole body and visceral fat mass, were observed Natarajan, H. et al, ASBMR 2025 We plan to initiate a Phase 2 clinical trial of rinvatercept in patients with DMD in the first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/keros-corporatepresentat.htm)) |
| February 10, 2026 | [Translarna™ (ataluren) primary completion](https://sec-api.dev/pdufa/ataluren) | PTCT | Duchenne Muscular Dystrophy | withdrawn | "NCT01247207 (Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor PTC Therapeutics; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01247207)) |
| March 10, 2026 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| March 11, 2026 | [SGT-003 interim data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne muscular dystrophy | completed, positive | "On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy ("Duchenne") at a dose level of 1E14vg/kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/sldb-20260311.htm)) |
| June 26, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | scheduled | "On June 26, 2026, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration ("FDA") is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application ("BLA") seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy ("DMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926078327/capr-20260626x8k.htm)) |
| August 24, 2026 | [PRECISION BIOSCIENCES INC trial start](https://sec-api.dev/companies/dtil/catalysts) | DTIL | Duchenne muscular dystrophy | completed | "On August 24, 2026, Precision BioSciences, Inc. (the "Company") issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy ("DMD") at Arkansas Children's Hospital." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm)) |
| September 2026 | [RGX-202 primary completion](https://sec-api.dev/pdufa/rgx-202) | RGNX | Duchenne Muscular Dystrophy | delayed | "NCT05693142 (AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor REGENXBIO Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05693142)) |
| September 28, 2026 | [Rinvatercept trial start](https://sec-api.dev/pdufa/rinvatercept) | KROS | Duchenne muscular dystrophy | completed | "On September 28, 2026, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm)) |
| Q4 2026 | [RGX-202 topline data readout](https://sec-api.dev/pdufa/rgx-202) | RGNX | Duchenne Muscular Dystrophy | scheduled | "Subretinal wet AMD topline pivotal data expected in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| January 2027 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05540860)) |
| Jan to Apr 2027 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05540860)) |
| March 2027 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100887)) |
| Mar to Jun 2027 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100887)) |
| May to Aug 2027 | [ELEVIDYS (delandistrogene moxeparvovec) topline data readout](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT | Duchenne Muscular Dystrophy | scheduled | "NCT05881408 (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05881408)) |
| May 2027 | [ELEVIDYS (delandistrogene moxeparvovec) primary completion](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) | SRPT | Duchenne Muscular Dystrophy | scheduled | "NCT05881408 (A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05881408)) |
| Aug to Nov 2028 | [Rinvatercept topline data readout](https://sec-api.dev/pdufa/rinvatercept) | KROS | Duchenne Muscular Dystrophy | scheduled | "NCT07704099 (Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Keros Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07704099)) |
| August 2028 | [Rinvatercept primary completion](https://sec-api.dev/pdufa/rinvatercept) | KROS | Duchenne Muscular Dystrophy | scheduled | "NCT07704099 (Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Keros Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07704099)) |
| January 2029 | [SGT-003 primary completion](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne Muscular Dystrophy | scheduled | "NCT07160634 (A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Solid Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160634)) |
| Jan to Apr 2029 | [SGT-003 topline data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne Muscular Dystrophy | scheduled | "NCT07160634 (A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Solid Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07160634)) |
| March 2029 | [Wve-n531 primary completion](https://sec-api.dev/pdufa/wve-n531) | WVE | Duchenne Muscular Dystrophy | scheduled | "NCT07209332 (Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Wave Life Sciences USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209332)) |
| Mar to Jun 2029 | [Wve-n531 topline data readout](https://sec-api.dev/pdufa/wve-n531) | WVE | Duchenne Muscular Dystrophy | scheduled | "NCT07209332 (Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Wave Life Sciences USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209332)) |

## Drugs

- [Vasculan® (ifetroban)](https://sec-api.dev/pdufa/ifetroban) (CPIX)
- [SGT-003](https://sec-api.dev/pdufa/sgt-003) (SLDB)
- [Deramiocel](https://sec-api.dev/pdufa/deramiocel) (CAPR)
- [INS1201](https://sec-api.dev/pdufa/ins1201) (INSM)
- [Pgn-edo51](https://sec-api.dev/pdufa/pgn-edo51) (PEPG)
- [Fordadistrogene movaparvovec](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) (PFE)
- [Rostudirsen](https://sec-api.dev/pdufa/rostudirsen) (DYN)
- [Rinvatercept](https://sec-api.dev/pdufa/rinvatercept) (KROS)
- [Translarna™ (ataluren)](https://sec-api.dev/pdufa/ataluren) (PTCT)
- [RGX-202](https://sec-api.dev/pdufa/rgx-202) (RGNX)
- [Sevasemten](https://sec-api.dev/pdufa/sevasemten) (EWTX)
- [ELEVIDYS (delandistrogene moxeparvovec)](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) (SRPT)
- [Wve-n531](https://sec-api.dev/pdufa/wve-n531) (WVE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/duchenne-muscular-dystrophy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Duchenne muscular dystrophy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/duchenne-muscular-dystrophy

```bibtex
@misc{secapidev_indications_duchenne_muscular_dystrophy_20261116,
  title        = {Duchenne muscular dystrophy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/duchenne-muscular-dystrophy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_duchenne_muscular_dystrophy_20261116","title":"Duchenne muscular dystrophy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/duchenne-muscular-dystrophy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
